Sun Pharmaceutical Industries Limited announced its Q3FY26 results with sales up by 15.1% YoY to ₹154,691 million. Net profit increased by 16.0% YoY to ₹33,688 million. The Board declared an interim dividend of ₹11.00 per share. Global Innovative Medicines sales reached US$423 million, including a US$55 million milestone payment.
Financial Performance
Sun Pharma reported a strong Q3FY26, demonstrating growth across its key business segments. Key highlights include:
- Sales: ₹154,691 million, up 15.1% YoY
- EBITDA: ₹49,485 million, up 23.4%, with an EBITDA margin of 31.9%
- Net Profit: ₹33,688 million, up 16.0% YoY
Segmental Performance
The company experienced growth in its India, Emerging Markets and Global Innovative Medicines businesses. A breakdown of sales by geography shows:
- India Formulations: ₹49,986 million, up 16.2%
- US Formulations: US$477 million, a marginal increase of 0.6%, accounting for approximately 27.5% of total consolidated sales.
- Emerging Markets: US$337 million, up 21.6%, contributing 19.4% to total sales.
- Rest of World: US$296 million, up 14.5%, accounting for 17.1% of total sales.
Innovative Medicines Portfolio
Global Innovative Medicines sales were US$423 million for Q3FY26, which included a US$55 million milestone payment. Excluding the milestone, these sales were up 13.2% and accounted for 21.2% of sales.
Dividend Declaration
The Board of Directors declared an interim dividend of ₹11.00 per equity share for the financial year FY26.
R&D Investment
Sun Pharma continues to invest in research and development, with ₹8,928 million, or 5.8% of sales, allocated to R&D during the quarter.
Source: BSE
